Conjunctivitis Market Size, Share, and Trends 2024 to 2034

The global conjunctivitis market size is calculated at USD 5.56 billion in 2025 and is forecasted to reach around USD 8.66 billion by 2034, accelerating at a CAGR of 5.05% from 2025 to 2034. The North America conjunctivitis market size surpassed USD 1.90 billion in 2024 and is expanding at a CAGR of 5.22% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

  • Last Updated : January 2025
  • Report Code : 1230
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Conjunctivitis Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Conjunctivitis Market

5.1. Covid-19: Conjunctivitis Industry Impact
5.2. Conjunctivitis Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Conjunctivitis Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Conjunctivitis Market Players to deal with Covid-19 Pandemic Scenario

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Increased exposure to chemicals and pollutants
6.1.1.2. Rising awareness of condition
6.1.2. Market Restraints
6.1.2.1. Lack of Self Awareness
6.1.3. Market Opportunities
6.1.3.1. Exploring specific treatment for viral conjunctivitis

Chapter 7. Global Conjunctivitis Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Conjunctivitis Market Revenue by Market Players
7.1.1.2. Conjunctivitis Market Revenue Market Share by Market Players
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Conjunctivitis Market, By Type

8.1. Conjunctivitis Market, by Type, 2025-2034
8.1.1. Bacterial Conjunctivitis
8.1.1.1. Market Revenue and Forecast (2022-2034)
8.1.2. Viral Conjunctivitis
8.1.2.1. Market Revenue and Forecast (2022-2034)
8.1.3. Allergic Conjunctivitis
8.1.3.1. Market Revenue and Forecast (2022-2034)

Chapter 9. Global Conjunctivitis Market, By Patients Type

9.1. Conjunctivitis Market, by Application, 2025-2034
9.1.1. Pediatric
9.1.1.1. Market Revenue and Forecast (2022-2034)
9.1.2. Adults
9.1.2.1. Market Revenue and Forecast (2022-2034)

Chapter 10. Global Conjunctivitis Market, By Drug Class

10.1. Conjunctivitis Market, by Application, 2025-2034
10.1.1. Antibiotics
10.1.1.1. Market Revenue and Forecast (2022-2034)
10.1.2. Anti-Histaminic
10.1.2.1. Market Revenue and Forecast (2022-2034)
10.1.3. Decongestant
10.1.3.1. Market Revenue and Forecast (2022-2034)
10.1.4. Steroid Drugs
10.1.4.1. Market Revenue and Forecast (2022-2034)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2022-2034)

Chapter 11. Global Conjunctivitis Market, Regional Estimates and Trend Forecast

11.1. North America
11.1.1. Market Revenue Forecast by Type(2022-2034)
11.1.2. Market Revenue Forecast by Patients Type (2022-2034)
11.1.3. Market Revenue Forecast by Drug Class (2022-2034)
11.1.4. U.S
11.1.4.1. Market Revenue Forecast (2022-2034)
11.1.5. Canada
11.1.5.1. Market Revenue Forecast (2022-2034)
11.2. Europe
11.2.1. Market Revenue Forecast by Type (2022-2034)
11.2.2. Market Revenue Forecast by Patients Type (2022-2034)
11.2.3. Market Revenue Forecast by Drug Class (2022-2034)
11.2.4. UK
11.2.4.1. Market Revenue Forecast (2022-2034)
11.2.5. Germany
11.2.5.1. Market Revenue Forecast (2022-2034)
11.2.6. France
11.2.6.1. Market Revenue Forecast (2022-2034)
11.2.7. Rest of EU
11.2.7.1. Market Revenue Forecast (2022-2034)
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Type (2022-2034)
11.3.2. Market Revenue Forecast by Patients Type (2022-2034)
11.3.3. Market Revenue Forecast by Drug Class (2022-2034)
11.3.4. China
11.3.4.1. Market Revenue Forecast (2022-2034)
11.3.5. India
11.3.5.1. Market Revenue Forecast (2022-2034)
11.3.6. Japan
11.3.6.1. Market Revenue Forecast (2022-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue Forecast (2022-2034)
11.4. LATAM
11.4.1. Market Revenue Forecast by Type (2022-2034)
11.4.2. Market Revenue Forecast by Patients Type (2022-2034)
11.4.3. Market Revenue Forecast by Drug Class (2022-2034)
11.4.4. Brazil
11.4.4.1. Market Revenue Forecast (2022-2034)
11.4.5. Rest of LATAM
11.4.5.1. Market Revenue Forecast (2022-2034)
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Type (2022-2034)
11.5.2. Market Revenue Forecast by Patients Type (2022-2034)
11.5.3. Market Revenue Forecast by Drug Class (2022-2034)
11.5.4. GCC
11.5.4.1. Market Revenue Forecast (2022-2034)
11.5.5. North Africa
11.5.5.1. Market Revenue Forecast (2022-2034)
11.5.6. South Africa
11.5.6.1. Market Revenue Forecast (2022-2034)
11.5.7. Rest of MEA
11.5.7.1. Market Revenue Forecast (2022-2034)

Chapter 12. Company Profiles

12.1. Atopix Therapeutics Ltd.
12.1.1. Company Overview, Business Information, Regional Presence
12.1.2. Product Portfolio Analysis
12.1.2.1. Type Details, Specification, Application
12.1.3. Revenue, Price, and Gross Margin
12.1.4. Recent Developments and Strategies
12.2. Allegran
12.2.1. Company Overview, Business Information, Regional Presence
12.2.2. Product Portfolio Analysis
12.2.2.1. Type Details, Specification, Application
12.2.3. Revenue, Price, and Gross Margin
12.2.4. Recent Developments and Strategies
12.3. Ocular Therapeutix, Inc.
12.3.1. Company Overview, Business Information, Regional Presence
12.3.2. Product Portfolio Analysis
12.3.2.1. Type Details, Specification, Application
12.3.3. Revenue, Price, and Gross Margin
12.3.4. Recent Developments and Strategies
12.4. Santen Pharmaceutical Co. Ltd.
12.4.1. Company Overview, Business Information, Regional Presence
12.4.2. Product Portfolio Analysis
12.4.2.1. Type Details, Specification, Application
12.4.3. Revenue, Price, and Gross Margin
12.4.4. Recent Developments and Strategies
12.5. Novartis
12.5.1. Company Overview, Business Information, Regional Presence
12.5.2. Product Portfolio Analysis
12.5.2.1. Type Details, Specification, Application
12.5.3. Revenue, Price, and Gross Margin
12.5.4. Recent Developments and Strategies
12.6. Boehringer Ingelheim
12.6.1. Company Overview, Business Information, Regional Presence
12.6.2. Product Portfolio Analysis
12.6.2.1. Type Details, Specification, Application
12.6.3. Revenue, Price, and Gross Margin
12.6.4. Recent Developments and Strategies
12.7. Boehringer Ingelheim
12.7.1. Company Overview, Business Information, Regional Presence
12.7.2. Product Portfolio Analysis
12.7.2.1. Type Details, Specification, Application
12.7.3. Revenue, Price, and Gross Margin
12.7.4. Recent Developments and Strategies
12.8. Sun Pharma
12.8.1. Company Overview, Business Information, Regional Presence
12.8.2. Product Portfolio Analysis
12.8.2.1. Type Details, Specification, Application
12.8.3. Revenue, Price, and Gross Margin
12.8.4. Recent Developments and Strategies
12.9. Sirion Therapeutics, Inc.
12.9.1. Company Overview, Business Information, Regional Presence
12.9.2. Product Portfolio Analysis
12.9.2.1. Type Details, Specification, Application
12.9.3. Revenue, Price, and Gross Margin
12.9.4. Recent Developments and Strategies
12.10. Company 10
12.10.1. Company Overview, Business Information, Regional Presence
12.10.2. Product Portfolio Analysis
12.10.2.1. Type Details, Specification, Application
12.10.3. Revenue, Price, and Gross Margin
12.10.4. Recent Developments and Strategies

Chapter 13. Appendix

13.1. About Us
13.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

According to Precedence Research, the global conjunctivitis market size was reached at USD 5.29 billion in 2024 and is projected to hit over USD 8.66 billion by 2034.

The global conjunctivitis market is exhibiting at a CAGR of 5.05% during forecast period 2025 to 2034.

Factors such as increasing prevalence of conjunctivitis, increasing healthcare expenditure, rising exposure to allergens, highly contagious nature of conjunctivitis are driving the growth of conjunctivitis market. Moreover, Additional features that are expected to fuel this business are integration of latest technologies and growing investment by major players.

The North America region dominated the worldwide market with a market share of higher than 36% In 2024.

The Asia Pacific region is projected to grow at the highest CAGR in the estimate period due to increasing healthcare expenditure.

Among the type segment, allergic conjunctivitis dominated the overall market in 2024. High prevalence of allergic conjunctivitis due to high exposure to allergen is the foremost factors attributing to its large market share.

The key companies functioning in the worldwide conjunctivitis market are Atopix Therapeutics Ltd., Allegran, Ocular Therapeutix, Inc., Santen Pharmaceutical Co. Ltd., Novartis, Boehringer Ingelheim, Pfizer Inc, Allegran, Sun Pharma, and Sirion Therapeutics, Inc. among others.

Conjunctivitis is a contamination of the conjunctiva, a slim membrane layering the white portion of the sclera, eye, or the internal surface of the lids. Conjunctivitis can be very contagious and expand easily within large collections of people. Occasionally, especially in children, the ailment can affect visualization. In such situations, clinicians need to be knowledgeable immediately for effective and primary treatment.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client